Labetalol HCl (Page 4 of 4)

Potential Adverse Effects

In addition, other adverse effects not listed above have been reported with other beta-adrenergic blocking agents.

Central Nervous System

Reversible mental depression progressing to catatonia, an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on psychometrics.

Cardiovascular

Intensification of A-V block [see Contraindications].

Allergic

Fever combined with aching and sore throat, laryngospasm, respiratory distress.

Hematologic

Agranulocytosis, thrombocytopenic or nonthrombocytopenic purpura.

Gastrointestinal

Mesenteric artery thrombosis, ischemic colitis.

The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with labetalol hydrochloride.

Clinical Laboratory Tests

There have been reversible increases of serum transaminases in 4% of patients treated with labetalol hydrochloride and tested and, more rarely, reversible increases in blood urea.

OVERDOSAGE

Overdosage with labetalol hydrochloride causes excessive hypotension that is posture sensitive and, sometimes, excessive bradycardia. Patients should be placed supine and their legs raised, if necessary, to improve the blood supply to the brain. If overdosage with labetalol hydrochloride follows oral ingestion, gastric lavage or pharmacologically induced emesis (using syrup of ipecac) may be useful for removal of the drug shortly after ingestion. The following additional measures should be employed if necessary:

Excessive bradycardia

Administer atropine or epinephrine.

Cardiac failure

Administer a digitalis glycoside and a diuretic. Dopamine or dobutamine may also be useful.

Hypotension

Administer vasopressors, e.g., norepinephrine. There is pharmacologic evidence that norepinephrine may be the drug of choice.

Bronchospasm

Administer epinephrine and/or an aerosolized beta2 -agonist.

Seizures

Administer diazepam.

In severe beta-blocker overdose resulting in hypotension and/or bradycardia, glucagon has been shown to be effective when administered in large doses (5 mg to 10 mg rapidly over 30 seconds, followed by continuous infusion of 5 mg per hour that can be reduced as the patient improves).

Neither hemodialysis nor peritoneal dialysis removes a significant amount of labetalol hydrochloride from the general circulation (less than 1%).

The oral LD50 value of labetalol hydrochloride in the mouse is approximately 600 mg/kg and in the rat is greater than 2 g/kg. The intravenous LD50 in these species is 50 mg/kg to 60 mg/kg.

DOSAGE AND ADMINISTRATION

DOSAGE MUST BE INDIVIDUALIZED. The recommended initial dosage is 100 mg twice daily whether used alone or added to a diuretic regimen. After 2 or 3 days, using standing blood pressure as an indicator, dosage may be titrated in increments of 100 mg b.i.d. (twice daily) every 2 or 3 days. The usual maintenance dosage of labetalol hydrochloride tablets is between 200 mg and 400 mg twice daily.

Since the full antihypertensive effect of labetalol hydrochloride tablets is usually seen within the first 1 to 3 hours of the initial dose or dose increment, the assurance of a lack of an exaggerated hypotensive response can be clinically established in the office setting. The antihypertensive effects of continued dosing can be measured at subsequent visits, approximately 12 hours after a dose, to determine whether further titration is necessary.

Patients with severe hypertension may require from 1200 mg to 2400 mg per day, with or without thiazide diuretics. Should side effects (principally nausea or dizziness) occur with these doses administered b.i.d.(twice daily), the same total daily dose administered t.i.d. (three times daily) may improve tolerability and facilitate further titration. Titration increments should not exceed 200 mg b.i.d. (twice daily).

When a diuretic is added, an additive antihypertensive effect can be expected. In some cases this may necessitate a labetalol hydrochloride tablet dosage adjustment. As with most antihypertensive drugs, optimal dosages of labetalol hydrochloride tablets are usually lower in patients also receiving a diuretic.

When transferring patients from other antihypertensive drugs, labetalol hydrochloride tablets should be introduced as recommended and the dosage of the existing therapy progressively decreased.

Elderly Patients

As in the general patient population, labetalol therapy may be initiated at 100 mg twice daily and titrated upwards in increments of 100 mg b.i.d. (twice daily) as required for control of blood pressure. Since some elderly patients eliminate labetalol more slowly, however, adequate control of blood pressure may be achieved at a lower maintenance dosage compared to the general population. The majority of elderly patients will require between 100 mg and 200 mg b.i.d. (twice daily).

HOW SUPPLIED

Labetalol Hydrochloride Tablets, USP, for oral administration, are available as

100 mg

Round, white, film-coated tablets, debossed “E” over “ 10” on one side and bisected on the other side and supplied as:

NDC 0185-0010-01 bottles of 100

NDC 0185-0010-05 bottles of 500

NDC 0185-0010-10 bottles of 1000

200 mg

Round, white, film-coated tablets, debossed “E” over “ 117” on one side and bisected on the other side and supplied as:

NDC 0185-0117-01 bottles of 100

NDC 0185-0117-05 bottles of 500

NDC 0185-0117-10 bottles of 1000

300 mg

Round, white, film-coated tablets, debossed “E” over “ 118” on one side and plain on the other side and supplied as:

NDC 0185-0118-01 bottles of 100

NDC 0185-0118-05 bottles of 500

NDC 0185-0118-10 bottles of 1000

Labetalol Hydrochloride Tablets, USP should be stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP with a child-resistant closure as required.

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Manufactured by

Sandoz Inc.

Princeton, NJ 08540

Rev. October 2016

MF0010REV10/16

Labetalol Hydrochloride Tablets, USP, 100 mg x 100 Tablets — Label

NDC 0185-0010-01

Labetalol Hydrochloride Tablets, USP

100 mg

Rx only

100 Tablets

Sandoz

10mgx100Tabs
(click image for full-size original)

Labetalol Hydrochloride Tablets, USP, 200 mg x 100 Tablets — Label

NDC 0185-0117-01

Labetalol Hydrochloride Tablets, USP

200 mg

Rx only

100 Tablets

Sandoz

200mgx100Tabs
(click image for full-size original)

Labetalol Hydrochloride Tablets, USP, 300 mg x 100 Tablets “Unscored” — Label

NDC 0185-0118-01

Labetalol Hydrochloride Tablets, USP

300 mg

Rx only

100 Tablets

Sandoz

300mgx100Tabs
(click image for full-size original)
LABETALOL HCL
labetalol hcl tablet, film coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0185-0010
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
LABETALOL HYDROCHLORIDE (LABETALOL) LABETALOL HYDROCHLORIDE 100 mg
Inactive Ingredients
Ingredient Name Strength
STARCH, CORN
HYPROMELLOSE, UNSPECIFIED
LACTOSE MONOHYDRATE
MAGNESIUM STEARATE
POLYETHYLENE GLYCOL, UNSPECIFIED
POLYSORBATE 80
SODIUM STARCH GLYCOLATE TYPE A POTATO
TITANIUM DIOXIDE
Product Characteristics
Color WHITE Score 2 pieces
Shape ROUND Size 8mm
Flavor Imprint Code E10
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0185-0010-10 1000 TABLET, FILM COATED in 1 BOTTLE None
2 NDC:0185-0010-05 500 TABLET, FILM COATED in 1 BOTTLE None
3 NDC:0185-0010-01 100 TABLET, FILM COATED in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA075113 08/04/1998
LABETALOL HCL
labetalol hcl tablet, film coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0185-0117
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
LABETALOL HYDROCHLORIDE (LABETALOL) LABETALOL HYDROCHLORIDE 200 mg
Inactive Ingredients
Ingredient Name Strength
STARCH, CORN
HYPROMELLOSE, UNSPECIFIED
LACTOSE MONOHYDRATE
MAGNESIUM STEARATE
POLYETHYLENE GLYCOL, UNSPECIFIED
POLYSORBATE 80
SODIUM STARCH GLYCOLATE TYPE A POTATO
TITANIUM DIOXIDE
Product Characteristics
Color WHITE Score 2 pieces
Shape ROUND Size 10mm
Flavor Imprint Code E117
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0185-0117-10 1000 TABLET, FILM COATED in 1 BOTTLE None
2 NDC:0185-0117-05 500 TABLET, FILM COATED in 1 BOTTLE None
3 NDC:0185-0117-01 100 TABLET, FILM COATED in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA075113 08/04/1998
LABETALOL HCL
labetalol hcl tablet, film coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0185-0118
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
LABETALOL HYDROCHLORIDE (LABETALOL) LABETALOL HYDROCHLORIDE 300 mg
Inactive Ingredients
Ingredient Name Strength
STARCH, CORN
HYPROMELLOSE, UNSPECIFIED
LACTOSE MONOHYDRATE
MAGNESIUM STEARATE
POLYETHYLENE GLYCOL, UNSPECIFIED
POLYSORBATE 80
SODIUM STARCH GLYCOLATE TYPE A POTATO
TITANIUM DIOXIDE
Product Characteristics
Color WHITE Score no score
Shape ROUND Size 11mm
Flavor Imprint Code E118
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:0185-0118-10 1000 TABLET, FILM COATED in 1 BOTTLE None
2 NDC:0185-0118-05 500 TABLET, FILM COATED in 1 BOTTLE None
3 NDC:0185-0118-01 100 TABLET, FILM COATED in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA075113 08/04/1998
Labeler — Eon Labs, Inc. (012656273)

Revised: 10/2018 Eon Labs, Inc.

Page 4 of 4 1 2 3 4

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.